Kodiak Sciences Q3 EPS Estimate Reduced by Zacks Research

Key Points

• Investment analysts at Zacks Research have downgraded Kodiak Sciences' Q3 2025 earnings estimates, now predicting a loss of ($1.03) per share, down from a prior estimate of ($0.99).
• Analysts have issued mixed ratings on the stock, with Barclays adjusting its target price from $4.00 to $7.00 while JPMorgan upgraded it to a neutral rating with a target price of $15.00.
• Kodiak Sciences is currently valued with a market cap of $451.61 million and has a twelve-month stock price range from $1.92 to $11.60.

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Equities research analysts at Zacks Research dropped their Q3 2025 earnings estimates for Kodiak Sciences in a report issued on Wednesday, September 3rd. Zacks Research analyst Team now anticipates that the company will earn ($1.03) per share for the quarter, down from their prior estimate of ($0.99). The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. Zacks Research also issued estimates for Kodiak Sciences' Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($4.17) EPS, Q1 2026 earnings at ($0.92) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.84) EPS, Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.88) EPS and FY2027 earnings at ($3.50) EPS.

A number of other analysts have also recently issued reports on the stock. Barclays increased their price objective on shares of Kodiak Sciences from $4.00 to $7.00 and gave the stock an "underweight" rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. raised shares of Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price objective for the company in a research note on Thursday, August 14th. Finally, HC Wainwright increased their price objective on shares of Kodiak Sciences from $3.00 to $5.00 and gave the stock a "neutral" rating in a research note on Monday, August 18th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $11.75.

Kodiak Sciences Stock Performance

Shares of NASDAQ KOD traded down $0.27 during midday trading on Friday, reaching $9.79. The stock had a trading volume of 95,459 shares, compared to its average volume of 450,257. The stock has a 50-day moving average of $7.53 and a 200-day moving average of $4.91. The company has a market capitalization of $517.18 million, a price-to-earnings ratio of -2.60 and a beta of 2.44. Kodiak Sciences has a 12-month low of $1.92 and a 12-month high of $11.60.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.02).

Hedge Funds Weigh In On Kodiak Sciences

Hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company purchased a new position in shares of Kodiak Sciences in the fourth quarter worth $902,000. GSA Capital Partners LLP grew its stake in shares of Kodiak Sciences by 163.6% in the 1st quarter. GSA Capital Partners LLP now owns 205,833 shares of the company's stock worth $577,000 after buying an additional 127,748 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in shares of Kodiak Sciences in the 1st quarter worth $28,000. XTX Topco Ltd purchased a new position in shares of Kodiak Sciences in the 1st quarter worth $126,000. Finally, Nuveen LLC purchased a new position in shares of Kodiak Sciences in the 1st quarter worth $392,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.